InvestorBrandNetworknews

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast 

Wednesday, September 30, 2026IBN.aiView original
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Co-Founder and Executive Co-Chair Anthony Durkacz returned to The BioMedWire Podcast to discuss the company’s Lucid-MS drug candidate, which is advancing to a Phase 2 trial in multiple sclerosis patients, as well as […]